FMP
Histogen Inc.
HSTO
NASDAQ
Inactive Equity
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
0.02 USD
0 (0%)
PennyStocks
Mar 20, 2023
Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Mar 18, 2023
Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
InvestorPlace
Mar 17, 2023
Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.
Zacks Investment Research
Jan 10, 2023
Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PennyStocks
Nov 10, 2022
Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
May 17, 2022
SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Steven J. Mento, Ph.D., Histogen's Executive Chairman and Interim President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference.
GlobeNewsWire
Apr 28, 2022
SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen's financial results for the first quarter ended March 31, 2022 will be released after the close of market on Thursday, May 12, 2022.
PennyStocks
Apr 19, 2022
Top penny stocks to watch under $1 in April if you like Biotech stocks. The post 5 Top Biotech Penny Stocks Under $1 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
Apr 12, 2022
Check these 3 under $1 biotech penny stocks out for your list The post Top Biotech Penny Stocks to Buy Under $1? 3 Exploding Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
GlobeNewsWire
Mar 3, 2022
SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function, today announced that Histogen's financial results for the fourth quarter and year ended December 31, 2021 will be released after the close of market on Thursday, March 10, 2022.